Walker A M
Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA.
Contraception. 1998 Mar;57(3):169-81. doi: 10.1016/s0010-7824(98)00014-6.
Research on the relationship between venous thromboembolism and the progestagen content of combined oral contraceptives has pointed to an increase in risk associated with products containing desogestrel and gestodene. Although many biases must have been at play in these nonexperimental studies, the errors that have been suggested and examined are not of a sufficient magnitude to account for the observed results. The most plausible explanation of the available data is that combined oral contraceptives containing desogestrel and gestodene carry a very small risk of venous thromboembolism, which exceeds the even smaller risk carried by products containing levonorgestrel. The position of norgestimate is uncertain.
关于静脉血栓栓塞与复方口服避孕药中孕激素含量之间关系的研究表明，含去氧孕烯和孕二烯酮的产品会增加风险。尽管在这些非实验性研究中肯定存在许多偏差，但已提出并检验的误差程度不足以解释观察到的结果。对现有数据最合理的解释是，含去氧孕烯和孕二烯酮的复方口服避孕药有非常小的静脉血栓栓塞风险，该风险超过了含左炔诺孕酮产品所带来的更小风险。诺孕酯的情况尚不确定。
